These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 30630956)

  • 1. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
    Blumenfeld AM; Tepper SJ; Robbins LD; Manack Adams A; Buse DC; Orejudos A; D Silberstein S
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):353-360. PubMed ID: 30630956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
    Blumenfeld AM; Aurora SK; Laranjo K; Papapetropoulos S
    BMC Neurol; 2015 Jul; 15():100. PubMed ID: 26133547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
    Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatigue, sleep-wake pattern, depressive and anxiety symptoms and body-mass index: analysis in a sample of episodic and chronic migraine patients.
    Lucchesi C; Baldacci F; Cafalli M; Dini E; Giampietri L; Siciliano G; Gori S
    Neurol Sci; 2016 Jun; 37(6):987-9. PubMed ID: 26879311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF
    J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
    Winner PK; Blumenfeld AM; Eross EJ; Orejudos AC; Mirjah DL; Adams AM; Brin MF
    Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD; Diener HC; Dodick DW; Sommer K; Lipton RB
    Headache; 2024; 64(7):838-848. PubMed ID: 38982666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
    Lipton RB; Rosen NL; Ailani J; DeGryse RE; Gillard PJ; Varon SF
    Cephalalgia; 2016 Aug; 36(9):899-908. PubMed ID: 27288354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
    d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
    J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.